Label Free Detection Market Size, Share & Trends by Offering (Instrument, Consumables, Software, Services), Technology, Application - Global Forecast to 2029
세계의 무표지 검출 시장 규모는 2024년 5억 1,500만 달러로 추정되고, 2029년까지 7억 4,700만 달러에 이를 것으로 예측되며, 2024년부터 2029년까지 예측 기간에 CAGR 7.7%로 성장이 예상됩니다.
시장의 성장은 창약에서의 이용을 위한 제약기업 및 바이오테크놀러지 기업에서의 채용 증가, 혁신적인 제품의 개발과 발매를 위한 주요 기업에 의한 연구개발 투자 증가, 무표지 검출 기술의 지속적인 진보에 의해 크게 견인되고 있습니다. 그러나 높은 장비 비용과 무표지 탐지의 기술적 제약은 시장 성장을 억제합니다.
| 조사 범위 |
| 조사 대상년도 |
2022-2029년 |
| 기준년 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
100만 달러 |
| 부문 |
제공별, 기술별, 용도별, 최종 사용자별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
'소모품 부문의 바이오센서 칩 부문은 2023년에 제공별로 가장 큰 점유율을 차지했습니다.'
바이오센서는 다양한 분석물을 검출하는 수단을 제공함으로써 생화학과 생체의학 공학 분야에서 귀중한 기구가 되고 있습니다. 무표지 바이오센서는 현재 단백질체학 및 생체분자간 상호작용 연구에서 인기가 있습니다. 많은 미량 화합물은 일반적으로 크로마토그래피 기술에 의해 검출되지만, 이 기술은 일반적으로 고가이고 대규모이며 전문 지식을 필요로 합니다. 바이오 센서는 더 빠르고 저렴한 옵션을 제공합니다. 바이오센서는 실시간으로 모니터링할 수 있는 능력과 높은 특이성, 짧은 반응시간, 유기용매나 시료의 취급이 적어서 휴대가 가능하며 컴팩트한 설계, 간단한 조작 등 미소분자를 감지하는 전통적인 기술에는 없었던 여러 가지 이점을 제공합니다.
'미국이 2024년부터 2029년까지 예측 기간에 무표지 검출 시장을 계속 독점할 전망입니다.'
미국은 세계 최대의 바이오 의약품 시장이며 바이오 의약품의 연구 및 투자 리더입니다. 감염증 환자 증가, 바이오의약품의 중요성 증가, 의료 부문의 안전하고 고품질 제품의 필요성 등으로 무표지 검출 솔루션에 대한 수요는 향후 수년간 증가할 것으로 예상됩니다. 인프라 개발, 정부 지원, 민간 자금 조달로 인해 이 나라는 매우 발전된 연구개발 시장을 자랑합니다. 이로 인해 독창적이고 정교한 연구 기술이 발전하고 있습니다. 턴어라운드 시간을 단축하고, 에너지 효율이 뛰어나고, 신뢰성 높은 결과를 단시간에 제공하는 무표지 검출을 통해, 미국의 제약 기업은 새로운 시약이나 테스트 어세이의 작성에 적극적으로 협력해, 그것을 사용 하고 있습니다. 이러한 요소는 세계의 무표지 검출 산업의 확대에 기여합니다.
본 보고서는 세계의 무표지 검출 시장에 대해 조사 분석하여 주요 촉진요인 및 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
- 무표지 검출 시장 개요
- 북미의 무표지 검출 시장 점유율 : 제공별, 국가별(2023년)
- 아시아태평양의 무표지 검출 시장 : 최종 사용자별, 국가별(2023년)
- 무표지 검출 시장 점유율 : 최종 사용자별(2023년)
- 무표지 검출 시장 : 지리적 성장 기회
제5장 시장 개요
- 서문
- 시장 역학
- 고객의 비즈니스에 영향을 미치는 동향 및 혼란
- 기술 분석
- 공급망 분석
- 밸류체인 분석
- 가격 분석
- 생태계 분석
- 무표지 검출 시장 : 원재료 공급자의 역할
- 무표지 검출 시장 : 제조업체의 역할
- 무표지 검출 시장 : 최종 사용자의 역할
- 무표지 검출 시장 : 규제 기관의 역할
- 특허 분석
- 주요 컨퍼런스 및 이벤트(2024-2025년)
- 규제 상황
- 규제기관, 정부기관, 기타 조직
- 규제 시나리오
- Porter's Five Forces 분석
- 주요 이해관계자 및 구매 기준
- 투자 및 자금조달 시나리오
- 무표지 검출 시장에 대한 AI의 영향
- 무역 분석
제6장 무표지 검출 시장 : 제공별
제7장 무표지 검출 시장 : 기술별
- 서문
- 표면 플라즈몬 공명
- 시차 주사 열량 측정
- 바이오 레이어 간섭법
- 등온 적정 열량 측정
- 기타 기술
제8장 무표지 검출 시장 : 용도별
- 서문
- 결합 동역학
- 결합 열역학
- 히트 확인
- 리드 제너레이션
- 내인성 수용체 검출
- 기타 용도
제9장 무표지 검출 시장 : 최종 사용자별
- 서문
- 제약 기업 및 생명 공학 기업
- 학술기관 및 연구기관
- 개발 업무 수탁 기관
- 기타 최종 사용자
제10장 무표지 검출 시장 : 지역별
- 서문
- 북미
- 유럽
- 유럽의 거시경제 분석
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시경제 분석
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시경제 분석
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 아프리카
제11장 경쟁 구도
- 서문
- 주요 기업의 전략 및 유력 기업
- 수익 분배 분석
- 시장 점유율 분석
- 기업의 평가 매트릭스 : 주요 기업(2023년)
- 기업의 평가 매트릭스 : 스타트업 및 중소기업(2023년)
- 기업 평가 및 재무 지표
- 브랜드 및 제품 비교 분석
- 경쟁 시나리오
제12장 기업 프로파일
- 주요 기업
- DANAHER CORPORATION
- SARTORIUS AG
- AGILENT TECHNOLOGIES, INC.
- WATERS CORPORATION
- CORNING INCORPORATED
- REVVITY, INC.
- AMETEK, INC.
- HORIBA, LTD.
- SPECTRIS
- SHIMADZU CORPORATION
- HITACHI HIGH-TECH CORPORATION
- ATTANA AB
- BRUKER
- BIO-RAD LABORATORIES, INC.
- ENDRESS HAUSER GROUP SERVICES AG
- BECTON, DICKINSON AND COMPANY
- 기타 기업
- NANOTEMPER TECHNOLOGIES GMBH
- AFFINITE INSTRUMENTS
- BIOSENSING INSTRUMENT
- UNCHAINED LABS
- BIONAVIS LTD.
- GATOR BIO
- CARTERRA, INC.
- NICOYA
- BIOPTIX ANALYTICAL LLC
- PLEXERA BIOSCIENCE
- XANTEC BIOANALYTICS GMBH
- BMG LABTECH
- REDSHIFT BIOANALYTICS, INC.
- LINO BIOTECH AG
제13장 부록
AJY
The global label-free detection market is projected to reach USD 747 million by 2029 from USD 515 million in 2024, at a CAGR of 7.7% during the forecast period of 2024 to 2029. The growth of the Label-free detection market has been significantly driven by its increasing adoption among pharmaceutical and biotechnology companies for drug discovery application, increasing R&D investment by key players for the development and launch of innovative product and continuous advancements in label-free detection technologies. However, high instrument costs and the technical limitations of label-free detection are restraining market growth.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD Million) |
| Segments | Offering, Technology, Application, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The biosensor chips segment under consumables segment accounted for the largest share by offering in 2023."
In 2023, the biosensor chips segment under consumables segment accounted for the largest share by offerings in the global label-free detection market. Biosensors are valuable instruments in the domains of biochemistry and biomedical engineering, as they offer a means of detecting a range of analytes. Label-free biosensors are currently popular in proteomics and biomolecular interaction research because the transducer can detect the chemical or biological agent without the need for dyes, enzymes, or radiolabels. Many tiny compounds are typically found via chromatographic techniques, which are typically expensive, large, and need specialized knowledge. Biosensors provide a quicker and less expensive option. Biosensors offer several benefits over traditional techniques for detecting tiny molecules, such as the ability to monitor in real-time, their high specificity, quick reaction times, minimal need for organic solvents and sample handling, portability, compact design, and simple operation.
"The US has continued to dominate the label-free detection market during the forecast period of 2024-2029."
The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, demand for label-free detection solutions is predicted to rise in the next years. Because of improved infrastructure, government assistance, and private financing, the country boasts a very developed R&D market. This advances creative and sophisticated research technologies. With label-free detection, which offers reduced turnaround time, and is energy-efficient and provides reliable results, with in a span of time, pharmaceutical companies in the US are actively collaborating in the creation of new reagent and test assays and using it. These elements help the global label-free detection industry to expand.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
Danaher Corporation (US)
Sartorius AG (Germany)
Waters Corporation (US)
REVVITY, INC. (US)
Ametek, Inc. (US)
Horiba, Ltd. (Japan)
Spectris (UK)
Corning Incorporated (US)
Agilent Technologies, Inc. (US)
Shimadzu Corporation (Japan)
Hitachi High-Tech Corporation (Japan)
Attana AB (Sweden)
Bruker Corporation (US)
Bio-Rad Laboratories (US)
ENDRESS+HAUSER Group Services AG (Switzerland)
Becton, Dickinson and Company (US)
Nanotemper Technologies GmBH (Germany)
Affinite Instruments (Canada)
Biosensing Instrument (US)
Unchained Labs.(US)
BioNavis Ltd. (Finland)
Gator Bio (US)
Carterra, Inc. (US)
Nicoya Lifesciences Inc., (Canada)
BiOptix Analytical LLC (US)
Plexera Bioscience (US)
XanTec bioanalytics GmbH (Germany)
BMG Labtech (Germany)
RedShift BioAnalytics, Inc. (US)
lino Biotech AG (Switzerland)
Research Coverage:
This research report categorizes the label-free detection market by offering (Instruments, Consumables (Biosesor Chips, Microplates, Reagents & Kits), Software & Services), by Technology (Surface Plasmon Resonance, Differential Scanning Calorimetry, Bio-layer Interferometry, Isothermal Titration Calorimetry and Other Technologies), by Application (Binding Kinetics, Binding Thermodynamics, HIT Confirmation, Lead Generation, Endogenous Receptor Detection, and Other Application) by end user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organization, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Label-free detection market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the Label-free detection market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall label-free detection market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Technological advancements in label-free detection, Growing academic-industrial partnerships for drug discovery programs, High sensitivity of label-free technologies, Increasing R&D investments in biotechnology and pharmaceuticals), restraints (High cost of instruments, Technical complexity), opportunities (Growing life sciences research in emerging economies, Rising demand for label-free detection technologies in point of care and portable devices for rapid and on-site analysis in various industry, Increased focus on biomarker discovery), and Challenges (Sample complexity and interference, Stringent regulatory approval process) influencing the growth of the market).
- Product Development/Innovation: Detailed insights on newly launched products of the label-free detection market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the label-free detection market
- Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Waters Corporation (US), Agilent Technologies, Inc. (US), Corning Incorporated (US), REVVITY, INC. (US), Ametek, Inc. (US), Horiba, Ltd. (Japan), Spectris (UK), Shimadzu Corporation (Japan), Hitachi High-Tech Corporation (Japan), Attana AB (Sweden), Bruker Corporation (US), Bio-Rad Laboratories (US), ENDRESS+HAUSER Group Services AG (Switzerland), Becton, Dickinson and Company (US), among others in the market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 MARKET STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH APPROACH
- 2.1.1 SECONDARY RESEARCH
- 2.1.2 PRIMARY RESEARCH
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.2 INSIGHTS OF PRIMARY EXPERTS
- 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RISK ASSESSMENT
- 2.7 MARKET LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 LABEL-FREE DETECTION MARKET OVERVIEW
- 4.2 NORTH AMERICA: LABEL-FREE DETECTION MARKET SHARE, BY OFFERING AND COUNTRY (2023)
- 4.3 ASIA PACIFIC: LABEL-FREE DETECTION MARKET, BY END USER & COUNTRY (2023)
- 4.4 LABEL-FREE DETECTION MARKET SHARE, BY END USER, 2023
- 4.5 LABEL-FREE DETECTION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Technological advancements
- 5.2.1.2 Growing academic-industrial partnerships for drug discovery programs
- 5.2.1.3 High sensitivity of label-free technologies
- 5.2.1.4 Increasing R&D investments in biotechnology and pharmaceuticals
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of instruments
- 5.2.2.2 Technical complexity
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Growing life science research in emerging economies
- 5.2.3.2 Rising demand for label-free detection technologies in point-of-care and portable devices for rapid and on-site analysis in various industries
- 5.2.3.3 Increased focus on biomarker discovery
- 5.2.4 CHALLENGES
- 5.2.4.1 Sample complexity and interference
- 5.2.4.2 Stringent regulatory approval process
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 TECHNOLOGY ANALYSIS
- 5.4.1 KEY TECHNOLOGIES
- 5.4.1.1 Surface plasmon resonance (SPR)
- 5.4.1.2 Bio-layer interferometry (BLI)
- 5.4.1.3 Isothermal titration calorimetry (ITC)
- 5.4.2 COMPLEMENTARY TECHNOLOGIES
- 5.4.2.1 Microfluidics
- 5.4.2.2 Artificial intelligence (AI)
- 5.4.2.3 Optical coherence tomography (OCT)
- 5.4.3 ADJACENT TECHNOLOGIES
- 5.4.3.1 Mass spectrometry
- 5.4.3.2 Flow cytometry
- 5.4.3.3 Confocal microscopy
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 PRICING ANALYSIS
- 5.8 ECOSYSTEM ANALYSIS
- 5.8.1 LABEL-FREE DETECTION MARKET: ROLE OF RAW MATERIAL SUPPLIERS
- 5.8.2 LABEL-FREE DETECTION MARKET: ROLE OF MANUFACTURERS
- 5.8.3 LABEL-FREE DETECTION MARKET: ROLE OF END USERS
- 5.8.4 LABEL-FREE DETECTION MARKET: ROLE OF REGULATORY BODIES
- 5.9 PATENT ANALYSIS
- 5.9.1 PATENT METHODOLOGY
- 5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2023
- 5.9.3 INNOVATION & PATENT APPLICATIONS
- 5.9.4 TOP APPLICANTS
- 5.10 KEY CONFERENCES & EVENTS IN 2024-2025
- 5.11 REGULATORY LANDSCAPE
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11.2 REGULATORY SCENARIO
- 5.12 PORTER'S FIVE FORCES ANALYSIS
- 5.12.1 THREAT OF NEW ENTRANTS
- 5.12.2 THREAT OF SUBSTITUTES
- 5.12.3 BARGAINING POWER OF BUYERS
- 5.12.4 BARGAINING POWER OF SUPPLIERS
- 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.13.2 KEY BUYING CRITERIA FOR LABEL-FREE DETECTION PRODUCTS
- 5.14 INVESTMENT & FUNDING SCENARIO
- 5.15 IMPACT OF AI ON LABEL-FREE DETECTION MARKET
- 5.16 TRADE ANALYSIS
6 LABEL-FREE DETECTION MARKET, BY OFFERING
- 6.1 INTRODUCTION
- 6.2 INSTRUMENTS
- 6.2.1 TECHNOLOGICAL ADVANCEMENTS IN LABEL-FREE DETECTION SYSTEMS TO DRIVE INSTRUMENTS MARKET
- 6.3 CONSUMABLES
- 6.3.1 BIOSENSOR CHIPS
- 6.3.1.1 High specificity and need for real-time monitoring of molecular interactions to drive adoption
- 6.3.2 MICROPLATES
- 6.3.2.1 Low cost to propel adoption among research laboratories and academic institutes
- 6.3.3 REAGENTS & KITS
- 6.3.3.1 Availability of ready-to-use kits for assay development to drive market
- 6.4 SOFTWARE & SERVICES
- 6.4.1 AUTOMATION BENEFITS IN LABEL-FREE DETECTION TO SUPPORT DEMAND GROWTH
7 LABEL-FREE DETECTION MARKET, BY TECHNOLOGY
- 7.1 INTRODUCTION
- 7.2 SURFACE PLASMON RESONANCE
- 7.2.1 GROWING USE OF SPR TECHNOLOGY IN AFFINITY AND KINETIC STUDIES TO FUEL MARKET GROWTH
- 7.3 DIFFERENTIAL SCANNING CALORIMETRY
- 7.3.1 WIDE USAGE IN DRUG DISCOVERY AND DEVELOPMENT FOR PROTEIN CHARACTERIZATION TO DRIVE MARKET
- 7.4 BIO-LAYER INTERFEROMETRY
- 7.4.1 MICROFLUIDICS-FREE NATURE OF BLI TO DRIVE MARKET
- 7.5 ISOTHERMAL TITRATION CALORIMETRY
- 7.5.1 RISING USE IN LABEL-FREE MEASUREMENT OF BINDING AFFINITY AND THERMODYNAMICS TO PROPEL MARKET GROWTH
- 7.6 OTHER TECHNOLOGIES
8 LABEL-FREE DETECTION MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 BINDING KINETICS
- 8.2.1 BINDING KINETICS TO HOLD LARGEST MARKET SHARE
- 8.3 BINDING THERMODYNAMICS
- 8.3.1 WIDE USAGE IN BASIC RESEARCH FOR DRUG MECHANISM ANALYSIS TO SUPPORT MARKET GROWTH
- 8.4 HIT CONFIRMATION
- 8.4.1 BENEFITS OVER OTHER APPROACHES FOR HTS TO DRIVE ADOPTION OF LABEL-FREE TECHNOLOGY
- 8.5 LEAD GENERATION
- 8.5.1 DATA GENERATION CAPABILITIES IN DRUG CANDIDATE SELECTION PROCESS TO SUPPORT DEMAND
- 8.6 ENDOGENOUS RECEPTOR DETECTION
- 8.6.1 HIGH SENSITIVITY OF LABEL-FREE ASSAYS TO PROPEL USAGE
- 8.7 OTHER APPLICATIONS
9 LABEL-FREE DETECTION MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 GROWING ADOPTION OF LFD TECHNOLOGIES TO FUEL MARKET GROWTH
- 9.3 ACADEMIC & RESEARCH INSTITUTES
- 9.3.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR RESEARCH TO DRIVE MARKET
- 9.4 CONTRACT RESEARCH ORGANIZATIONS
- 9.4.1 INCREASING PHARMACEUTICAL OUTSOURCING TO DRIVE MARKET GROWTH
- 9.5 OTHER END USERS
10 LABEL-FREE DETECTION MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
- 10.2.2 US
- 10.2.2.1 US to dominate North American label-free detection market during study period
- 10.2.3 CANADA
- 10.2.3.1 Increasing government support and funding for life science research to promote market growth
- 10.3 EUROPE
- 10.3.1 EUROPE: MACROECONOMIC ANALYSIS
- 10.3.2 GERMANY
- 10.3.2.1 Increasing public and private funding for advanced cell-based research to drive market
- 10.3.3 UK
- 10.3.3.1 Increasing R&D spending by government and pharmaceutical companies to fuel market growth
- 10.3.4 FRANCE
- 10.3.4.1 Rising government healthcare investments and increasing focus on genomic medicine research to aid market growth
- 10.3.5 ITALY
- 10.3.5.1 Increased focus on healthcare research and rising funding for new drug development to propel market growth
- 10.3.6 SPAIN
- 10.3.6.1 Rising focus on personalized and translational medicine development to drive market
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
- 10.4.2 CHINA
- 10.4.2.1 Improved medical service quality and growth in biopharmaceutical sector to drive market
- 10.4.3 JAPAN
- 10.4.3.1 High R&D expenditure and improved healthcare access to stimulate market growth
- 10.4.4 INDIA
- 10.4.4.1 Increasing R&D spending by pharmaceutical companies and growing government initiatives to drive market
- 10.4.5 AUSTRALIA
- 10.4.5.1 Strategic geographical location and favorable regulatory environment to augment market growth
- 10.4.6 SOUTH KOREA
- 10.4.6.1 Technological advancements and high healthcare spending to boost market growth
- 10.4.7 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
- 10.5.2 BRAZIL
- 10.5.2.1 Increased incidence of chronic diseases and improved public access to modern healthcare facilities to drive market
- 10.5.3 MEXICO
- 10.5.3.1 Favorable trade agreements and government initiatives to spur market growth
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST
- 10.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
- 10.6.2 GCC COUNTRIES
- 10.6.2.1 Saudi Arabia
- 10.6.2.1.1 Growing healthcare expenditure and increasing research institutes to boost market growth
- 10.6.2.2 UAE
- 10.6.2.2.1 Adoption of advanced label-free detection products for research to aid market growth
- 10.6.2.3 Rest of GCC Countries
- 10.6.3 REST OF MIDDLE EAST
- 10.7 AFRICA
- 10.7.1 GROWING PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE MARKET
- 10.7.2 AFRICA: MACROECONOMIC ANALYSIS
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE LABEL-FREE DETECTION MARKET
- 11.3 REVENUE SHARE ANALYSIS
- 11.4 MARKET SHARE ANALYSIS
- 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 11.5.5.1 Company footprint
- 11.5.5.2 Offering footprint
- 11.5.5.3 Technology footprint
- 11.5.5.4 Application footprint
- 11.5.5.5 Region footprint
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 11.7 COMPANY VALUATION AND FINANCIAL METRICS
- 11.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES/ENHANCEMENTS/UPGRADES
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
- 11.9.4 OTHER DEVELOPMENTS
12 COMPANY PROFILES
- 12.1 KEY PLAYERS
- 12.1.1 DANAHER CORPORATION
- 12.1.1.1 Business overview
- 12.1.1.2 Products offered
- 12.1.1.3 Recent developments
- 12.1.1.3.1 Expansions
- 12.1.1.3.2 Other developments
- 12.1.1.4 MnM view
- 12.1.1.4.1 Key strengths
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 SARTORIUS AG
- 12.1.2.1 Business overview
- 12.1.2.2 Products offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Product launches/enhancements/upgrades
- 12.1.2.3.2 Expansions
- 12.1.2.4 MnM view
- 12.1.2.4.1 Key strengths
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 AGILENT TECHNOLOGIES, INC.
- 12.1.3.1 Business overview
- 12.1.3.2 Products offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Product launches/enhancements/upgrades
- 12.1.3.4 MnM view
- 12.1.3.4.1 Key strengths
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 WATERS CORPORATION
- 12.1.4.1 Business overview
- 12.1.4.2 Products offered
- 12.1.4.3 Recent developments
- 12.1.4.3.1 Product launches/enhancements/upgrades
- 12.1.4.4 MnM view
- 12.1.4.4.1 Key strengths
- 12.1.4.4.2 Strategic choices
- 12.1.4.4.3 Weaknesses & competitive threats
- 12.1.5 CORNING INCORPORATED
- 12.1.5.1 Business overview
- 12.1.5.2 Products offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Product launches/enhancements/upgrades
- 12.1.5.4 MnM view
- 12.1.5.4.1 Key strengths
- 12.1.5.4.2 Strategic choices
- 12.1.5.4.3 Weaknesses and competitive threats
- 12.1.6 REVVITY, INC.
- 12.1.6.1 Business overview
- 12.1.6.2 Products offered
- 12.1.6.3 Recent developments
- 12.1.6.3.1 Other developments
- 12.1.7 AMETEK, INC.
- 12.1.7.1 Business overview
- 12.1.7.2 Products offered
- 12.1.8 HORIBA, LTD.
- 12.1.8.1 Business overview
- 12.1.8.2 Products offered
- 12.1.9 SPECTRIS
- 12.1.9.1 Business overview
- 12.1.9.2 Products offered
- 12.1.9.3 Recent developments
- 12.1.9.3.1 Product launches/enhancements/upgrades
- 12.1.9.3.2 Deals
- 12.1.10 SHIMADZU CORPORATION
- 12.1.10.1 Business overview
- 12.1.10.2 Products offered
- 12.1.11 HITACHI HIGH-TECH CORPORATION
- 12.1.11.1 Business overview
- 12.1.11.2 Products offered
- 12.1.12 ATTANA AB
- 12.1.12.1 Business overview
- 12.1.12.2 Products offered
- 12.1.13 BRUKER
- 12.1.13.1 Business overview
- 12.1.13.2 Products offered
- 12.1.13.3 Recent developments
- 12.1.13.3.1 Product launches/enhancements/upgrades
- 12.1.14 BIO-RAD LABORATORIES, INC.
- 12.1.14.1 Business overview
- 12.1.14.2 Products offered
- 12.1.15 ENDRESS+HAUSER GROUP SERVICES AG
- 12.1.15.1 Business overview
- 12.1.15.2 Products offered
- 12.1.15.3 Recent developments
- 12.1.16 BECTON, DICKINSON AND COMPANY
- 12.1.16.1 Business overview
- 12.1.16.2 Products offered
- 12.1.16.3 Recent developments
- 12.1.16.3.1 Product launches/enhancements/upgrades
- 12.2 OTHER PLAYERS
- 12.2.1 NANOTEMPER TECHNOLOGIES GMBH
- 12.2.2 AFFINITE INSTRUMENTS
- 12.2.3 BIOSENSING INSTRUMENT
- 12.2.4 UNCHAINED LABS
- 12.2.5 BIONAVIS LTD.
- 12.2.6 GATOR BIO
- 12.2.7 CARTERRA, INC.
- 12.2.8 NICOYA
- 12.2.9 BIOPTIX ANALYTICAL LLC
- 12.2.10 PLEXERA BIOSCIENCE
- 12.2.11 XANTEC BIOANALYTICS GMBH
- 12.2.12 BMG LABTECH
- 12.2.13 REDSHIFT BIOANALYTICS, INC.
- 12.2.14 LINO BIOTECH AG
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATIONS OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
